Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Immunotherapy and immune evasion in prostate cancer.

Cancers

Thakur A, Vaishampayan U, Lum LG.
PMID: 24216992
Cancers (Basel). 2013 May 24;5(2):569-90. doi: 10.3390/cancers5020569.

Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achieves debulking...

Cite
Thakur A, Vaishampayan U, Lum LG. Immunotherapy and immune evasion in prostate cancer. Cancers (Basel). 2013;5(2):569-90doi: 10.3390/cancers5020569.
Thakur, A., Vaishampayan, U., & Lum, L. G. (2013). Immunotherapy and immune evasion in prostate cancer. Cancers, 5(2), 569-90. https://doi.org/10.3390/cancers5020569
Thakur, Archana, et al. "Immunotherapy and immune evasion in prostate cancer." Cancers vol. 5,2 (2013): 569-90. doi: https://doi.org/10.3390/cancers5020569
Thakur A, Vaishampayan U, Lum LG. Immunotherapy and immune evasion in prostate cancer. Cancers (Basel). 2013 May 24;5(2):569-90. doi: 10.3390/cancers5020569. PMID: 24216992; PMCID: PMC3730318.
Copy Download .nbib Format: NLM
Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations.

ISRN minimally invasive surgery

Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Choi M, Heilbrun LK, Goodman AC.
PMID: 25621178
ISRN Minim Invasive Surg. 2012;2012. doi: 10.5402/2012/942364.

PURPOSE: To assess feasibility, complications, local tumor recurrences, overall survival (OS) and estimates of cost-effectiveness for multi-site cryoablation (MCA) of oligo-metastatic colorectal cancer (mCRC) in a prospective study.MATERIALS AND METHODS: 111 CT and/or US-guided percutaneous MCA procedures were performed...

Cite
Bang HJ, Littrup PJ, Currier BP, et al. Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations. ISRN Minim Invasive Surg. 2012;2012doi: 10.5402/2012/942364.
Bang, H. J., Littrup, P. J., Currier, B. P., Goodrich, D. J., Choi, M., Heilbrun, L. K., & Goodman, A. C. (2012). Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations. ISRN minimally invasive surgery, 2012. https://doi.org/10.5402/2012/942364
Bang, Hyun J, et al. "Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations." ISRN minimally invasive surgery vol. 2012 (2012). doi: https://doi.org/10.5402/2012/942364
Bang HJ, Littrup PJ, Currier BP, Goodrich DJ, Choi M, Heilbrun LK, Goodman AC. Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations. ISRN Minim Invasive Surg. 2012;2012. doi: 10.5402/2012/942364. PMID: 25621178; PMCID: PMC4301442.
Copy Download .nbib Format: NLM
A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy.

Journal of personalized medicine

Chen W, Bepler G.
PMID: 24349760
J Pers Med. 2013 Sep 01;3(3). doi: 10.3390/jpm3030251.

UNLABELLED: Platinum-based chemotherapy is a primary treatment of choice for advanced non-small-cell lung cancer (NSCLC). Analytical methods to specifically evaluate biomarkers predictive of therapeutic efficacy have not been developed. Two randomized phase III trials of carboplatin-based chemotherapy in advanced...

Cite
Chen W, Bepler G. A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy. J Pers Med. 2013;3(3)doi: 10.3390/jpm3030251.
Chen, W., & Bepler, G. (2013). A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy. Journal of personalized medicine, 3(3), . https://doi.org/10.3390/jpm3030251
Chen, Wei, and Bepler, Gerold. "A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy." Journal of personalized medicine vol. 3,3 (2013). doi: https://doi.org/10.3390/jpm3030251
Chen W, Bepler G. A method for biomarker directed survival prediction in advanced non-small-cell lung cancer patients treated with Carboplatin-based therapy. J Pers Med. 2013 Sep 01;3(3). doi: 10.3390/jpm3030251. PMID: 24349760; PMCID: PMC3859458.
Copy Download .nbib Format: NLM
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.

Journal for immunotherapy of cancer

Lum LG, Al-Kadhimi Z, Deol A, Kondadasula V, Schalk D, Tomashewski E, Steele P, Fields K, Giroux M, Liu Q, Flaherty L, Simon M, Thakur A.
PMID: 34117114
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002194.

BACKGROUND: Metastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors. This phase II trial...

Cite
Lum LG, Al-Kadhimi Z, Deol A, et al. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer. J Immunother Cancer. 2021;9(6)doi: 10.1136/jitc-2020-002194.
Lum, L. G., Al-Kadhimi, Z., Deol, A., Kondadasula, V., Schalk, D., Tomashewski, E., Steele, P., Fields, K., Giroux, M., Liu, Q., Flaherty, L., Simon, M., & Thakur, A. (2021). Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer. Journal for immunotherapy of cancer, 9(6), . https://doi.org/10.1136/jitc-2020-002194
Lum, Lawrence G, et al. "Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer." Journal for immunotherapy of cancer vol. 9,6 (2021). doi: https://doi.org/10.1136/jitc-2020-002194
Lum LG, Al-Kadhimi Z, Deol A, Kondadasula V, Schalk D, Tomashewski E, Steele P, Fields K, Giroux M, Liu Q, Flaherty L, Simon M, Thakur A. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer. J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002194. PMID: 34117114; PMCID: PMC8202097.
Copy Download .nbib Format: NLM
The molecular genomics of metastatic brain tumours.

OA molecular oncology

Bollig-Fischer A, Michelhaugh S, Ali-Fehmi R, Mittal S.
PMID: 25400938
OA Mol Oncol. 2013 Apr 01;1(1). doi: 10.13172/2052-9635-1-1-759.

INTRODUCTION: Metastatic brain tumours remain an intractable clinical problem despite notable advances in the treatment of the primary cancers. It is estimated that 30-40% of breast and lung cancer patients will develop brain metastases. Typically, brain lesions are not...

Cite
Bollig-Fischer A, Michelhaugh S, Ali-Fehmi R, et al. The molecular genomics of metastatic brain tumours. OA Mol Oncol. 2013;1(1)doi: 10.13172/2052-9635-1-1-759.
Bollig-Fischer, A., Michelhaugh, S., Ali-Fehmi, R., & Mittal, S. (2013). The molecular genomics of metastatic brain tumours. OA molecular oncology, 1(1), . https://doi.org/10.13172/2052-9635-1-1-759
Bollig-Fischer, A, et al. "The molecular genomics of metastatic brain tumours." OA molecular oncology vol. 1,1 (2013). doi: https://doi.org/10.13172/2052-9635-1-1-759
Bollig-Fischer A, Michelhaugh S, Ali-Fehmi R, Mittal S. The molecular genomics of metastatic brain tumours. OA Mol Oncol. 2013 Apr 01;1(1). doi: 10.13172/2052-9635-1-1-759. PMID: 25400938; PMCID: PMC4229688.
Copy Download .nbib Format: NLM
Bispecific antibodies for the treatment of breast cancer.

Expert opinion on biological therapy

Dillon PM, Tushir-Singh J, Lum LG.
PMID: 33896311
Expert Opin Biol Ther. 2021 May 09;1-11. doi: 10.1080/14712598.2021.1922665. Epub 2021 May 09.

INTRODUCTION: There are more than two dozen bispecific antibodies (BsAbs) in development with a variety of designs which are relevant to breast cancer. The field of BsAbs for breast cancer includes agents that co-direct immune recognition of the cancer...

Cite
Dillon PM, Tushir-Singh J, Lum LG. Bispecific antibodies for the treatment of breast cancer. Expert Opin Biol Ther. 2021;1-11doi: 10.1080/14712598.2021.1922665.
Dillon, P. M., Tushir-Singh, J., & Lum, L. G. (2021). Bispecific antibodies for the treatment of breast cancer. Expert opinion on biological therapy, 1-11. https://doi.org/10.1080/14712598.2021.1922665
Dillon, Patrick M, et al. "Bispecific antibodies for the treatment of breast cancer." Expert opinion on biological therapy vol. (2021): 1-11. doi: https://doi.org/10.1080/14712598.2021.1922665
Dillon PM, Tushir-Singh J, Lum LG. Bispecific antibodies for the treatment of breast cancer. Expert Opin Biol Ther. 2021 May 09;1-11. doi: 10.1080/14712598.2021.1922665. Epub 2021 May 09. PMID: 33896311; PMCID: PMC8576064.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries